Benjamin F. Edwards & Company’s ANI Pharmaceuticals ANIP Stock Holding History

Benjamin F. Edwards & Company’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-23	Closed	-$2K	–	2127
2024 Q1	$2K	Buy	+23	New	+$1.39K	﹤0.01%	2002
2019 Q1	–	Sell	-616	Closed	-$28K	–	1694
2018 Q4	$28K	Buy	616 +88	+17%	+$4.61K	﹤0.01%	994
2018 Q3	$30K	Buy	528 +132	+33%	+$8.08K	﹤0.01%	998
2018 Q2	$26K	Buy	396 +143	+57%	+$8.93K	﹤0.01%	1018
2018 Q1	$15K	Buy	+253	New	+$16.1K	﹤0.01%	1150
2017 Q2	–	Sell	-100	Closed	-$5K	–	1449
2017 Q1	$5K	Hold	100	–	–	﹤0.01%	1147
2016 Q4	$6K	Hold	100	–	–	﹤0.01%	1023
2016 Q3	$7K	Hold	100	–	–	﹤0.01%	897
2016 Q2	$6K	Hold	100	–	–	﹤0.01%	872
2016 Q1	$3K	Sell	100 -100	-50%	-$3.39K	﹤0.01%	968
2015 Q4	$9K	Buy	+200	New	+$8.61K	﹤0.01%	857

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Benjamin F. Edwards & Company's ANIP Position: Q2 2024 in Review

Benjamin F. Edwards & Company sold out of ANI Pharmaceuticals (ANIP) in Q2 2024, closing a stake of 23 shares — an estimated $2K sold.

Benjamin F. Edwards & Company first reported a position in ANIP in Q4 2015 and held it in 11 quarters. The position peaked at $30K in Q3 2018. 201 funds tracked by Wall St. Rank hold ANIP as of Q2 2024.

Benjamin F. Edwards & Company reported no remaining ANI Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Benjamin F. Edwards & Company sold 23 ANI Pharmaceuticals shares in Q2 2024, an estimated $2K.
Benjamin F. Edwards & Company first reported a position in ANI Pharmaceuticals in Q4 2015 and held it in 11 quarters.
Benjamin F. Edwards & Company's ANI Pharmaceuticals position peaked at $30K in Q3 2018.
201 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.